Hormonal
GLP-1 receptor agonists improve cardiovascular risk factors (blood pressure, lipid profiles, endothelial function) and reduce cardiovascular events in patients with type 2 diabetes and obesity.
GLP-1 injections not only help with weight and blood sugar but also improve heart health by lowering blood pressure, improving cholesterol, and reducing inflammation. They are recommended for patients with T2DM and obesity to reduce cardiovascular risk.
GLP-1 receptor agonists (GLP-1 RAs) represent significant progress in the treatment of T2DM patients because they affect a broad array of CVD RFs through body weight (BW) reduction, lipid level improvement, and positive effects on blood pressure (BP). ... Numerous CV trials have reported improvements in CV outcomes in patients treated with GLP-1 RAs. ... GLP-1 has pleiotropic CV effects, including anti-inflammatory effects, cardioprotection in ischemia, and decreased platelet aggregation.
Why this rating
Based on multiple CV outcome trials and mechanistic studies, though some mechanisms (e.g., direct BP effect) are not fully clarified.
Source
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović et al. · Journal of Cardiovascular Pharmacology and Therapeutics · 2022
DOI 10.1177/10742484221146371
More from this paper
- Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce significantly greater body weight loss and higher rates of prediabetes-to-normoglycemia conversion compared to GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and placebo in non-diabetic obese individuals.Strong
- GLP-1 receptor agonists (semaglutide, liraglutide, exenatide) significantly reduce body weight and improve glucose metabolism in non-diabetic obese individuals and those with prediabetes, often leading to normoglycemia.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →